Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2019-10-17 Director's Dealing
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-10-17 English
FORM 3/A SUBMISSION
Director's Dealing
2019-10-17 English
Director's Dealing 2019
Director's Dealing
2019-10-16 English
Director's Dealing 2019
Director's Dealing
2019-10-16 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 16, 2019, reporting specific corporate events including the resignation of a director, equity grants related to the IPO, and amendments to the certificate of incorporation and bylaws. The key content is about changes in the company's board of directors and corporate governance documents effective upon the IPO. There are no financial statements or detailed financial performance data present. The primary focus is on management and board changes and corporate governance amendments. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 5686 characters, which is sufficient to contain substantive information rather than a brief announcement. Hence, it is not a report publication announcement or regulatory filing fallback. Confidence is high due to clear identification of director resignation and governance changes.
2019-10-16 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, indemnification provisions, and exhibits related to corporate governance documents and stock plans. This type of filing is specifically related to registration of securities for employee compensation plans and is not a financial report, earnings release, or other types of filings listed. Therefore, it falls under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-10-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.